Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $29.20.
Several research firms have commented on KURA. Wedbush restated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the stock from $26.00 to $19.00 in a report on Monday. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Monday, September 9th.
Get Our Latest Stock Analysis on KURA
Institutional Investors Weigh In On Kura Oncology
Kura Oncology Price Performance
KURA opened at $18.21 on Wednesday. The stock’s 50-day moving average price is $19.58 and its 200 day moving average price is $20.27. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.39 and a beta of 0.84. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter last year, the firm posted ($0.53) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. As a group, sell-side analysts expect that Kura Oncology will post -2.45 earnings per share for the current year.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
- Five stocks we like better than Kura Oncology
- Market Cap Calculator: How to Calculate Market Cap
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- How to buy stock: A step-by-step guide for beginners
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Pros And Cons Of Monthly Dividend Stocks
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.